Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206245 · ClinicalTrials.gov registry record · Phase 2
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,400
- Enrollment target
NCT00206245 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 1,400 participants.
The verdict
NCT00206245, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 40 mg and to evaluate the safety and tolerability of AZD0865.
Interventions
- DRUG AZD0865
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206245
The ClinicalTrials.gov registry entry for NCT00206245 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD0865 is the first listed.
NCT00206245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206245 about?
NCT00206245 is a clinical study titled "A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.". The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 40 mg and to evaluate the safety and tolerability of AZD0865.
What is the current status of trial NCT00206245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,400 participants. The study started on 2004-05. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00206245?
The interventions under investigation include: AZD0865 (DRUG).
Who is sponsoring clinical trial NCT00206245?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.